Lumateperone 42 mg

DRUG6 trials

Sponsors

Intra-Cellular Therapies, Inc., Louisiana State University Health Sciences Center Shreveport, University of Texas at Austin, Massachusetts General Hospital, Jason Careri

Conditions

ApathyBipolar Depression Depressed PhaseEarly Life TraumaMajor Depressive DiorderObesity & OverweightPediatricSchizophreniaSchizophrenia; Psychosis

Phase 1

Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder

CompletedNCT04779177

Intra-Cellular Therapies, Inc.Pediatric, Schizophrenia

Start: 2021-03-12End: 2022-07-30Updated: 2025-11-12

Phase 3

Lumateperone for the Prevention of Relapse in Patients With Schizophrenia

CompletedNCT04959032

Intra-Cellular Therapies, Inc.Schizophrenia

Start: 2021-07-08End: 2024-08-07Updated: 2024-11-07

Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

RecruitingNCT06482554

Louisiana State University Health Sciences Center ShreveportApathy, Schizophrenia, Schizophrenia; Psychosis

Start: 2024-06-30End: 2026-12-31Target: 80Updated: 2024-07-01

Phase 4

Neurocircuitry Mechanisms and Efficacy of Lumateperone as Adjunctive Therapy for Major Depressive Disorder and History of Early Life Abuse

Not yet recruitingNCT07369115

University of Texas at AustinEarly Life Trauma, Major Depressive Diorder

Start: 2026-02-01End: 2030-01-01Target: 50Updated: 2026-01-27

The Effects of Lumateperone on Obesity and Physiologic Aging and Their Association With Antidepressant Response in Bipolar Depression

RecruitingNCT07699445

Massachusetts General HospitalBipolar Depression Depressed Phase, Obesity & Overweight

Start: 2026-09-09End: 2028-07-31Target: 25Updated: 2026-09-11

Caplyta Versus Placebo for Adults With Social Anxiety Disorder

RecruitingNCT07799493

Jason CareriSocial Anxiety Disorder (SAD)

Start: 2026-09-10End: 2028-05-28Target: 40Updated: 2026-09-15